AbbVie's Rinvoq shows superiority over Humira in head-to-head study
I'm PortAI, I can summarize articles.
AbbVie announced that its arthritis drug Rinvoq demonstrated superiority over Humira in a head-to-head trial involving 492 rheumatoid arthritis patients. The trial revealed that 43.3% of Rinvoq patients experienced improvement, compared to 22.4% for Humira. Additionally, 28.4% of Rinvoq patients showed no visible symptoms, versus 14.5% for Humira. AbbVie is relying on Rinvoq and Skyrizi to offset declining Humira sales following its patent expiration and the emergence of biosimilars.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments